From Chemotherapy to Targeted Pills: A New Era in Chronic Myeloid Leukemia and What Asciminib Could Mean for Patients ...

Getting a diagnosis of leukemia can feel overwhelming. But multiple treatment options and support organizations can help you on your journey after diagnosis. Leukemia is a type of cancer that affects ...

Personalized drug treatments have outperformed chemotherapy for leukemia patients in a trial led by Leeds researchers. Newly published, long-term results of the UK-wide FLAIR trial could transform ...

Leukemia symptoms include fatigue, weakness, chest pain, shortness of breath, bleeding, bruising, and increased infection risk due to altered blood cell counts. Recent leukemia treatment advancements ...

As part of consolidation therapy, patients may receive allogenic hematopoietic stem cell transplantation (HCT). HCT involves the replacement of a patient's normal source of bone marrow cells by ...

Inotuzumab ozogamicin is an anti-CD22 antibody-drug conjugate that is approved for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL). After binding CD22 on ...

ISTANBUL, TR / ACCESS Newswire / June 17, 2026 / Lymphocytic leukemia is a type of blood cancer that affects lymphocytes, a ...

Indiana University School of Medicine cancer researchers have identified a potential way to use existing, accessible drugs to ...

Blood cancer treatment is entering a new era, bringing powerful breakthroughs that offer renewed hope to people living with leukemia, lymphoma, myeloma, and other blood cancers. Cutting-edge targeted ...

Leukemia is a blood cancer with abnormal white blood cell overproduction, affecting red blood cells and platelets, leading to anemia and infection risks. Diagnosis involves blood tests, bone marrow ...

Imagine finding a “cure” for a type of cancer that’s long enjoyed the reputation of being aggressive and incurable. Thanks to recent trials, it’s no longer a dream — a groundbreaking scientific ...

Despite improved outcomes in newly diagnosed pediatric AML, relapsed disease remains a therapeutic challenge. Factors contributing to slow progress in improving outcomes include inherent challenges in ...